Wegovy Weekly Shot for Weight, Heart, Liver, and Teens 12+

People hear “semaglutide shot” and think one product. Regulators do not. Ozempic is labelled for type 2 diabetes (and related diabetes-class uses). Wegovy is the weight-class brand of the same active ingredient — with its own labelled doors for weight, heart-risk reduction in some countries, MASH in some countries, and teens 12+ only where the weight label says so. Same molecule in a different carton is still a different prescription path.

This episode is injectable Wegovy only. Oral Wegovy tablets and Foundayo (orforglipron) are Episode 3. Zepbound / tirzepatide weight and sleep apnea are Episode 2. The live Mounjaro heart-protection piece is a type 2 diabetes carton — cross-link only, not a rewrite. Compounded “semaglutide” is not an Access Level door.

Where this is taking place

Commercial path: a prescriber writes labelled Wegovy injection, a pharmacy dispenses a real Novo Nordisk carton, and you inject once weekly under the skin (abdomen, thigh, or upper arm) with a reduced-calorie diet and more activity. This is not a trial slot and not a compounding bench.

Key evidence programmes that sit under the labels (historical — not open enrolment doors for a first commercial script):

• Weight (adults): STEP programme (e.g. NCT03548935 and related STEP trials).
• Weight (ages 12+): STEP TEENS (NCT04102189).
• Cardiovascular risk reduction: SELECT (NCT03574597) — adults with established CV disease and overweight or obesity, without diabetes in the pivotal design used for the US CV claim.
• MASH (accelerated / conditional): ESSENCE (NCT04822181) — adults with noncirrhotic MASH and F2–F3 fibrosis; confirmatory outcomes still required where the label says so.

Series map (brief, not rehash): Foundayo (orforglipron) is the oral small-molecule weight door. Mounjaro CV (tirzepatide) is a type 2 diabetes heart-protection label — different brand family and different labelled population than Wegovy’s weight/CV story.

Approval matrix (Wegovy injection)

Use the label of the country that will prescribe. A US MASH accelerated line does not travel onto an EU pack that only carries weight management.

Access by country

• United States: Ask a clinician who manages obesity, cardiology risk, or MASH (as fits your door) about labelled Wegovy injection. FDA doors above. Usual maintenance for weight/CV: 1.7 or 2.4 mg once weekly after escalation from 0.25 → 0.5 → 1 → 1.7 → 2.4 mg (every 4 weeks). MASH maintenance on USPI: 2.4 mg weekly (may drop to 1.7 if not tolerated). Adults who tolerate 2.4 mg ≥4 weeks and need more weight reduction may go to a labelled maximum 7.2 mg weekly on the current US injection label — that is a US label fact, not a global default. Some UK public materials also discuss a 7.2 mg obesity path for BMI >30; Health Canada’s retrieved Product Monograph still frames maintenance at 2.4 mg — do not assume a Canadian 7.2 mg door. Do not combine with other semaglutide products or other GLP-1 RAs. Prior authorization still applies. No public-funding win is claimed here. Novo Nordisk Inc. adverse events: 1-833-934-6891; FDA MedWatch 1-800-FDA-1088. Pregnancy registry: 1-877-390-2760 / wegovypregnancyregistry.com.

• Canada (zoom, not a different Access Level): Health Canada–authorized Wegovy injection for weight (adults + eligible 12 to <18), non-fatal MI risk reduction (adults, established CVD, BMI ≥27), and MASH F2–F3 under NOC/c. A Notice of Compliance (with or without conditions) is not a provincial formulary listing. Public plan / NIHB / RAMQ listing status for these doors: unknown / not confirmed on this page — no listing win is claimed here. Private insurance and cash still require a labelled prescription. SAP is the wrong door for a marketed product. Do not mail-order a US pen as a Canadian care plan.

• United Kingdom: MHRA-labelled injection for weight (adults + adolescents where labelled) and for MASH under conditional authorisation (3 Jul 2026). GOV.UK: MASH use is not currently NHS. Ask the NHS/specialist team what is commissioned for weight vs MASH; do not assume one funding door covers every indication. Yellow Card for suspected side effects.

• EU/EEA: Commission-authorised weight door (adults + adolescents ≥12 with obesity and >60 kg). SELECT data inform the SmPC; no separate EU CV indication on the sources used here. Wegovy MASH EU status on this brand: not confirmed. National reimbursement lags country by country — unknown here unless a country file is opened.

• Australia: ARTG-registered for weight management including eligible adolescents 12+. Specialist/GP path per local rules. PBS unknown / not confirmed on this page.

• If your regulator has not authorised the door you need: do not import on your own. Ask a local clinician about legal special-access / named-patient rules only if those programs apply — or wait for a local label.

What it actually is

Wegovy injection is semaglutide, a GLP-1 receptor agonist, in a once-weekly subcutaneous pen or syringe. It is used with diet and activity.

It is not:

• Ozempic (different labelled doors — diabetes-class brand)
• Rybelsus (oral semaglutide diabetes tablet)
• Oral Wegovy tablets (Episode 3)
• Foundayo / orforglipron (Episode 3 cross-link)
• Mounjaro or Zepbound (tirzepatide — Episode 2 / live Mounjaro CV single)
• Compounded semaglutide
• A confirmatory cure for MASH
• Public coverage just because a regulator said yes

US injection escalation (all approved injection indications, adults and 12+): weeks 1–4: 0.25 mg; 5–8: 0.5 mg; 9–12: 1 mg; 13–16: 1.7 mg; then maintenance per indication (usually 2.4 mg recommended for weight/CV; 1.7 mg allowed). Missed dose (USPI): if next dose is >2 days away, take missed dose; if <2 days, skip and resume on schedule. Two or more consecutive misses: re-escalate from a lower dose as directed.

What the trials showed (plain numbers)

Weight — adults (STEP 1 pattern, US/HC labels): At ~68 weeks, people on Wegovy 2.4 mg lost on the order of ~15% of body weight vs low single-digit % on placebo in the pivotal obesity trial without diabetes (exact figures live on the USPI / Product Monograph tables). Most common reason people stop: stomach side effects during escalation.

Weight — ages 12+ (STEP TEENS): BMI fell on the order of ~16% on drug vs little change on placebo over 68 weeks in the adolescent obesity trial that supports the 12+ weight labels (US, Canada, EU, UK, Australia as matrixed). Gallbladder events were more common in teens than in adults on the US label.

Heart — SELECT (US CV indication; Canadian non-fatal MI claim; EU SmPC data): In ~17,600 adults with established CV disease and overweight/obesity without diabetes, weekly Wegovy cut the risk of the first major CV event (CV death, non-fatal MI, or non-fatal stroke) with hazard ratio about 0.80 vs placebo (USPI). Canada’s labelled CV sentence is narrower (non-fatal MI risk reduction) — use the Canadian monograph in Canada.

MASH — ESSENCE Part 1 (accelerated / NOC/c / UK conditional): Histology improvements in MASH resolution and fibrosis supported accelerated (FDA), NOC/c (Canada), and conditional (UK) authorisations in adults with F2–F3 fibrosis without cirrhosis. Confirmatory clinical-outcome evidence is still required. This is not a cure claim and not labelled for teens.

Safety a household should actually watch

Boxed / serious warning (US / Canada class language): Risk of thyroid C-cell tumours in rodents. Do not use if you or your family have medullary thyroid cancer (MTC) or MEN2.

Common: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dizziness, burping, reflux, hair loss — especially while doses climb.

Watch for and call urgently: severe persistent abdominal pain (pancreatitis), gallbladder pain, signs of severe allergic reaction, symptoms of low blood sugar if you also take insulin or a sulfonylurea, dehydration from vomiting/diarrhea (kidney injury risk), vision changes if you have diabetes and retinopathy history.

Other USPI watchpoints: heart-rate increase; delayed stomach emptying — tell surgeons/anesthesia teams before procedures; do not share multi-dose pens between people.

Pregnancy: May cause fetal harm. For weight/CV use, stop when pregnancy is recognized; plan pregnancy by stopping at least 2 months ahead (long half-life). MASH pregnancy language on the US label is benefit–risk with the clinician — not a casual continue.

Teens: Weight door only where labelled (12+). CV and MASH doors are adult on the labels used here.

Access: what you can actually do

1. Name the brand on the script: Wegovy — not Ozempic

If the clinic says “I’ll just write semaglutide,” ask which labelled brand and indication they mean. Diabetes-brand stock is not automatically the weight/CV/MASH Wegovy door.

2. Who to see

A clinician who already manages obesity, cardiometabolic risk, or liver/MASH (as fits your door): primary care, obesity medicine, endocrinology, cardiology, or hepatology. Bring: BMI or growth-chart percentile (teens), weight-related conditions, heart history (MI, stroke, PAD), liver fibrosis stage if known (F2–F3 vs cirrhosis), full med list (especially other GLP-1s, insulin, sulfonylureas), gallbladder history, pregnancy plans, and prior weight attempts.

3. Script for the visit

I am asking about labelled Wegovy injection, not Ozempic and not compounded semaglutide. On the US label, Wegovy injection covers weight (adults and ages 12+ with obesity), heart-risk reduction in adults with established cardiovascular disease and overweight or obesity, and accelerated approval for noncirrhotic MASH with F2–F3 fibrosis in adults. Health Canada authorizes weight (including eligible teens 12 to under 18), non-fatal MI risk reduction in eligible adults, and MASH under NOC/c. I want to know which door I fit in this country, whether you will prescribe the Wegovy carton, and what the realistic payment path is — private insurance, manufacturer support if any, or cash. I understand authorized is not funded, and MASH accelerated/conditional is not a confirmatory cure.

Ask:

• Which labelled indication applies to me here?
• Am I outside the label (under 12; cirrhosis; MEN2/MTC; pregnancy)?
• Escalation plan and what to do if I miss a week?
• How do we handle insurance prior authorization language (Wegovy / semaglutide 2.4 mg / indication)?
• Surgery or procedures coming up?

4. Payment honesty

Authorized ≠ funded. US commercial prior auth is common. Canadian public listing for these doors is not confirmed on this page — do not treat an NOC or NOC/c as a formulary win. UK MASH: not currently NHS per GOV.UK. Australia PBS: unknown / not confirmed. Episode 4 covers reimbursement process across the series doors.

5. Compounded products are not this door

If a spa, med-spa, or online seller offers “semaglutide” without a labelled Wegovy carton, that is not the Access Level path this episode maps.

6. Clinical trials

SELECT, STEP, and ESSENCE Part 1 support labels; they are not a 2026 walk-in enrolment path for a first commercial pen. Search ClinicalTrials.gov with your clinician only if you need a research door your local label does not cover.

7. If you are not a candidate

Under 12; personal/family MTC or MEN2; pregnancy (weight/CV stop rules); cirrhosis when the label says noncirrhotic MASH only; or a different molecule already labelled for your situation (see Episode 2 tirzepatide / Episode 3 orals). Ask for the labelled alternative — do not substitute brands in your head.

---

Bottom line

Wegovy injection is a real, labelled, once-weekly semaglutide shot with multiple doors: weight (adults and, where labelled, teens 12+), heart-risk reduction in adults with established CV disease and overweight/obesity (US full MACE claim; Canada non-fatal MI claim; EU data without a separate CV indication), and accelerated / conditional MASH treatment in adults with F2–F3 fibrosis without cirrhosis in the US, Canada, and UK. It is not Ozempic. It is not a MASH cure. It is not funded just because it is authorized. Ask for the Wegovy carton that matches your country’s label — then fight the payment step with eyes open.

---

Research team / Who (from primary sources only)

• Sponsor / MAH: Novo Nordisk A/S (EU); Novo Nordisk Inc. (US label contacts); Novo Nordisk Canada Inc. (Canadian Product Monograph).
• Pivotal programmes: STEP (weight), STEP TEENS (adolescent weight), SELECT / NCT03574597 (CV), ESSENCE / NCT04822181 (MASH). Named individual PIs appear only as on primary sources; no clinic phone directories are listed here.

Primary sources

1. FDA / DailyMed. WEGOVY (semaglutide) injection — Prescribing Information (setid ee06186f-2aa3-4990-a760-757579d8f77b; updated 18 Jun 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. FDA. Wegovy approval / supplement history — NDA 215256 (weight 4 Jun 2021; adolescent 23 Dec 2022; CV 8 Mar 2024; MASH accelerated 15 Aug 2025). https://www.accessdata.fda.gov/scripts/cder/daf/
3. FDA news. CV risk reduction approval (SELECT). https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
4. FDA news. MASH accelerated approval. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
5. Novo Nordisk Canada. WEGOVY Product Monograph (retrieved PDF; Date of Authorization 10 Dec 2025). https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/Wegovy-product-monograph.pdf
6. Health Canada. Qualifying notice / NOC/c materials for Wegovy MASH (Control 296143). https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/qualifying-notice-wegovy-296143.html
7. Health Canada. Regulatory Decision Summary — Wegovy MASH supplement. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1766074543990
8. EMA. Wegovy EPAR / product information (EU MA 6 Jan 2022; EMEA/H/C/005422). https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
9. MHRA / GOV.UK. Semaglutide (Wegovy) approved to treat form of liver disease — 3 Jul 2026 (conditional; not currently NHS for MASH). https://www.gov.uk/government/news/semaglutide-wegovy-approved-to-treat-form-of-liver-disease
10. TGA. Wegovy registrations / PI (weight; adolescents 12+). https://www.tga.gov.au/resources/prescription-medicines-registrations/wegovy-novo-nordisk-pharmaceuticals-pty-ltd-0
11. ClinicalTrials.gov. NCT03574597 (SELECT); NCT04822181 (ESSENCE); NCT04102189 (STEP TEENS); NCT03548935 (STEP 1).
12. Medcelerator live cross-links (do not rehash): https://medcelerator.com/articles/foundayo-orforglipron ; https://medcelerator.com/articles/mounjaro-tirzepatide-cv

---

Medcelerator Breaking Out Series #2 Episode 1 draft. Independent verification 2026-09-22 (America/Toronto). Access → Reviewer → Who → Chief before any publish. Not live. Not a substitute for a clinician who manages weight, heart risk, or MASH.